Key Proteo pilots newborn screening in Washington state

Written By Sean Sandin

January 2022 — Key Proteo started a newborn screening study in Washington state, targeting 50,000 newborns. Key Proteo will use its proprietary kits to identify Wilson disease, Wiskott-Aldrich syndrome, X-linked agammaglobulinemia, and Adenosine Deaminase deficiencies in newborns.

Sean Sandin
Previous

Key Proteo and Thermo-Fisher signed on MOU in August 2022
Next

Key Proteo develops first newborn testing kit prototype